Agios Pharmaceuticals Chief Medical Officer Sarah Gheuens filed a Form 4 on October 28, 2026, disclosing a same-day option exercise and sale of 7,866 shares of common stock on October 26, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercised: Gheuens acquired 7,866 shares of common stock via stock option exercise (transaction code M) at an exercise price of $25.01 per share on October 26, 2026.
  • Shares sold: 7,866 shares were disposed of (transaction code S) at a weighted average price of $37.69, with individual sale prices ranging from $37.53 to $38.06.
  • 10b5-1 plan: According to the filing, the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Gheuens.
  • Remaining common stock: Following the transactions, Gheuens directly beneficially owned 54,645 shares of common stock.
  • Remaining options: Gheuens holds 16,275 stock options (right to buy) remaining after the exercise, expiring March 1, 2033.
  • Option grant details: The exercised option was granted on March 1, 2023, with 25% vesting on March 1, 2024, and the remaining 75% vesting in 36 equal monthly installments thereafter.

Gheuens Option Exercise and Sale Details at Agios Pharmaceuticals

According to the Form 4 filed with the SEC on October 28, 2026, Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), reported two transactions in the company's common stock on October 26, 2026. First, Gheuens exercised stock options covering 7,866 shares at an exercise price of $25.01 per share, acquiring those shares directly. Immediately following, she disposed of the same 7,866 shares through an open-market sale.

The filing discloses that the shares were sold at a weighted average price of $37.69, with actual sale prices ranging from $37.53 to $38.06 per share. The filing notes that Gheuens "undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price." The sale was conducted under a pre-established Rule 10b5-1 trading plan.

After these transactions, Gheuens directly held 54,645 shares of Agios common stock. In Table II, the filing shows that 16,275 stock options remain outstanding, set to expire on March 1, 2033. The original option grant, dated March 1, 2023, vested 25% on March 1, 2024, with the balance vesting in 36 equal monthly installments thereafter. The Form 4 was signed by William Cook as attorney-in-fact for Sarah Gheuens on October 28, 2026.

What Was Disclosed

The filing reported the exercise of 7,866 stock options at $25.01 and the same-day sale of those shares at a weighted average of $37.69 under a 10b5-1 plan, leaving Gheuens with 54,645 shares and 16,275 remaining options.